Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study
- PMID: 29222916
- PMCID: PMC5991982
- DOI: 10.1002/hep.29723
Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study
Abstract
Under current guidelines, hepatitis C virus (HCV)-positive livers are not transplanted into HCV-negative recipients because of adverse posttransplant outcomes associated with allograft HCV infection. However, HCV can now be cured post-LT (liver transplant) using direct-acting antivirals (DAAs) with >90% success; therefore, HCV-negative patients on the LT waiting list may benefit from accepting HCV-positive organs with preemptive treatment. Our objective was to evaluate whether and in which HCV-negative patients the potential benefit of accepting an HCV-positive (i.e., viremic) organ outweighed the risks associated with HCV allograft infection. We developed a Markov-based mathematical model that simulated a virtual trial of HCV-negative patients on the LT waiting list to compare long-term outcomes in patients: (1) willing to accept any (HCV-negative or HCV-positive) liver versus (2) those willing to accept only HCV-negative livers. Patients receiving HCV-positive livers were treated preemptively with 12 weeks of DAA therapy and had a higher risk of graft failure than those receiving HCV-negative livers. The model incorporated data from published studies and the United Network for Organ Sharing (UNOS). We found that accepting any liver regardless of HCV status versus accepting only HCV-negative livers resulted in an increase in life expectancy when Model for End-Stage Liver Disease (MELD) was ≥20, and the benefit was highest at MELD 28 (0.172 additional life-years). The magnitude of clinical benefit was greater in UNOS regions with higher HCV-positive donor organ rates, that is, Regions 1, 2, 3, 10, and 11. Sensitivity analysis demonstrated that model outcomes were robust.
Conclusion: Transplanting HCV-positive livers into HCV-negative patients with preemptive DAA therapy could improve patient survival on the LT waiting list. Our analysis can help inform clinical trials and minimize patient harm. (Hepatology 2018;67:2085-2095).
© 2017 by the American Association for the Study of Liver Diseases.
Figures
![Figure 1](https://webcf.waybackmachine.org/web/20220408220607im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5991982/bin/nihms926624f1.gif)
![Figure 2](https://webcf.waybackmachine.org/web/20220408220607im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5991982/bin/nihms926624f2.gif)
![Figure 3](https://webcf.waybackmachine.org/web/20220408220607im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5991982/bin/nihms926624f3.gif)
![Figure 4](https://webcf.waybackmachine.org/web/20220408220607im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5991982/bin/nihms926624f4.gif)
![Figure 5](https://webcf.waybackmachine.org/web/20220408220607im_/https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5991982/bin/nihms926624f5.gif)
Comment in
-
Reply.Hepatology. 2018 Aug;68(2):793. doi: 10.1002/hep.30042. Hepatology. 2018. PMID: 29672882 No abstract available.
-
Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.Hepatology. 2018 Aug;68(2):792-793. doi: 10.1002/hep.30043. Hepatology. 2018. PMID: 29672899 Free PMC article. No abstract available.
Similar articles
-
Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy.Clin Gastroenterol Hepatol. 2019 Mar;17(4):739-747.e8. doi: 10.1016/j.cgh.2018.08.042. Epub 2018 Aug 21. Clin Gastroenterol Hepatol. 2019. PMID: 30138735 Free PMC article.
-
Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.Hepatology. 2017 Mar;65(3):777-788. doi: 10.1002/hep.28926. Epub 2017 Jan 6. Hepatology. 2017. PMID: 27906468 Free PMC article.
-
Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers.Liver Transpl. 2019 Dec;25(12):1800-1810. doi: 10.1002/lt.25644. Epub 2019 Oct 29. Liver Transpl. 2019. PMID: 31539195
-
Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.Curr Gastroenterol Rep. 2018 Apr 5;20(5):20. doi: 10.1007/s11894-018-0626-9. Curr Gastroenterol Rep. 2018. PMID: 29623506 Review.
-
Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".Am J Transplant. 2014 May;14(5):994-1002. doi: 10.1111/ajt.12714. Epub 2014 Apr 14. Am J Transplant. 2014. PMID: 24730431 Review.
Cited by 13 articles
-
Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier.World J Surg. 2021 Dec;45(12):3503-3510. doi: 10.1007/s00268-020-05924-1. Epub 2021 Jan 20. World J Surg. 2021. PMID: 33471156 Review.
-
Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C.Transplant Direct. 2020 Dec 8;7(1):e635. doi: 10.1097/TXD.0000000000001049. eCollection 2021 Jan. Transplant Direct. 2020. PMID: 33324740 Free PMC article.
-
Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients.Am J Transplant. 2021 Feb;21(2):657-668. doi: 10.1111/ajt.16245. Epub 2020 Sep 15. Am J Transplant. 2021. PMID: 32777173 Free PMC article.
-
Essential updates 2018/2019: Liver transplantation.Ann Gastroenterol Surg. 2020 Feb 25;4(3):195-207. doi: 10.1002/ags3.12321. eCollection 2020 May. Ann Gastroenterol Surg. 2020. PMID: 32490333 Free PMC article. Review.
-
Opioid epidemic and liver disease.JHEP Rep. 2019 Jul 9;1(3):240-255. doi: 10.1016/j.jhepr.2019.06.006. eCollection 2019 Sep. JHEP Rep. 2019. PMID: 32039374 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical